The difficulties encountered in treating older patients with acute myeloid leukemia (AML) are well known and include problems due to leukemia cell drug resistance and decreased tolerance of the side-effects of therapy. The definition of 'old' in treatment protocols has changed over the years, in part related to the increasing age at which allogeneic transplantation can be safely applied. Although the current arbitrary breakpoint at age 60 years seems to effectively distinguish patients with markedly different prognoses, there is likely to be a continuum of worsening outcome in patients in the 40-60-year-old group as well. Even in patients with apparent 'de novo' AML, CALGB trials consistently show long-term survival in only about 7% of older patients with AML. 1 Results in patients not selected for clinical trials may be even worse since certain minimal levels of organ function are required for entry on such protocols. In addition, as evidenced by the high incidence of unfavorable karyotypic changes found in older AML patients, a considerable fraction of patients probably had antecedent marrow disorders, which were not obvious from the patient's history.
Leukemias in older patients probably derive from a cell that is close to the hematopoietic stem cell. Hematopoietic precursors are designed to survive the repeated exposures to environmental (including bacterial and fungal) toxins, which are expected to be encountered during a lifetime. Virtually all resistance mechanisms that have been studied to date have been overexpressed in such cells. As demonstrated by marrow purging experiments, the hematopoietic stem cell can survive exposure to very large doses of cytotoxic agents in vitro. It is not surprising, therefore, that leukemias deriving from such immature progenitors are particularly resistant to cytotoxic agents. Indeed the complexity of the mutations in AML in older patients or in those with prior myelodysplasia may be more analogous to the multiple changes found in epithelial cancers than to the balanced translocations common in AML in younger patients. Thus, it would be surprising if cytotoxic agents turn out to be the long-term answer in the treatment of this disease.
Although there have been advances in the use of blood products and antibacterial, antifungal and antiviral agents, these have not had a substantial impact on overall survival in older patients with AML. Similarly, as noted in many randomized trials, hematopoietic growth factors have not affected complete response rates or survival. Arguably, the potent antiemetics have been one of the most important additions to our AML armamentarium, particularly in the treatment of older patients. For example, Candida esophagitis is now a rare problem, in part because patients no longer have severe vomiting, thereby decreasing erosions in the distal esophagus. Rectal infections, which were common in patients experiencing profound diarrhea from older antiemetics such as metoclopramide, occur much less frequently. Importantly, older people can routinely continue to eat while receiving intensive chemotherapy and hence are not nutritionally 'behind' as they were in the earlier days of chemotherapy. Nonetheless, although standard chemotherapy is now well tolerated by most older patients, drug resistance remains the critical impediment. Actually, in part related to improved overall supportive care, recent studies have shown that significant intensification of induction chemotherapy can be given to older patients, albeit without an obvious improvement in response rate. 2 Therefore, advances in the future will derive more from agents with better antileukemic effect than from further tuning up of supportive care.
Large numbers of randomized trials of induction chemotherapy have been conducted in patients with AML in the last 25 years with unfortunately no important improvements compared to standard treatment with an anthracycline and conventional dose cytosine arabinoside, particularly in older patients in whom the complete remission (CR) rate remains 50-60% depending on patient selection. 3 Treatment options for older patients who achieve remission include standarddose Ara-C regimens, high-dose Ara-C regimens, or investigational approaches. With regard to Ara-c, two randomized CALGB studies of post-remission therapy showed that there was no benefit from using high-or intermediate-dose regimens compared to standard-dose Ara-C in older patients, with the higher doses accompanied by substantially more toxicity and overall disease-free survival of approximately 10% of remitters. 4, 5 In addition, either because of prior medical problems or complications from the induction treatment, many older patients in CR are not candidates for further postremission therapy. Indeed, given the low cure rate, the point has been made that observation without further treatment might represent the best option for patients Ͼ60 years of age in terms of quality of life and reduced need for hospitalization. However, it is extremely unlikely that one would achieve any long-term, disease-free survival with no treatment at all. Unfortunately, at the moment it is difficult to predict who would most likely benefit from further therapy although obviously, patients with the most abnormal karyotypes are the least likely to be amongst the long-term survivors. Parenthetically, this is the problem that plagues oncologists constantly: treating 100 patients to help 10. Most clinicians offer conven-Leukemia tional-dose Ara-C (for example 100 mg/m 2 × 5 days for between three and four courses) to the majority of patients in first CR, in the hope of producing the occasional long-term response, but this must be an individualized decision.
Thus, older patients with AML are in dire need of more effective therapy. However, difficult challenges can also present unique opportunities. Since the median age of AML patients is now 60-65 years and probably rising, cooperative groups rapidly accrue older AML patients on clinical trials. The poor prognosis of these patients is consistent with the route by which many new anticancer drugs have been recently approved, ie by showing modest improvement in the 'worst' patient population with an 'unmet medical need'. Theoretically, because these patients do so badly, if a new agent is markedly effective, studies may be completed in a shorter period of time with fewer patients. A problem, of course, is that a focus on such patients presents a particularly high hurdle for new therapies and failure to demonstrate unequivocal activity against highly resistant disease may not exclude more marginal, but nonetheless important, benefit for younger patients or more favorable subtypes of AML.
There is no shortage of new non-cytotoxic approaches that are of interest including, and not limited to: farnesyl transferase inhibitors; immunologic manipulations; a host of antiangiogenic agents; tyrosine kinase inhibitors; other signal transduction inhibitors (either with specific or more generic enzymatic targets) and proteasome inhibitors. Many of these non-chemotherapeutic approaches also have the allure of oral treatment with potentially much less toxicity. Thus, there is a real imperative to develop efficient ways of studying compounds once they have shown a sufficient level of activity in preliminary studies (acknowledging the difficulties in screening drugs which may have more of a growth inhibitory rather than a cytotoxic effect).
There are a number of practical issues affecting the conduct of such trials in older patients:
(1) Evaluation of post remission manipulations is complicated by the low CR rate, so that only 40 to 50% of patients treated initially would be eligible for post-remission treatment. In addition, many such patients cannot receive postremission therapy because of compromised organ function from toxicities encountered during induction, as well as the fact that many older patients do not recover normal blood counts even after a significant antileukemic response during induction. In addition, many older patients decline further therapy, because they value the quality of life that CR can provide or the importance of upcoming family events and are not willing to take the risk of further hospitalization after conventional or experimental therapy. The fact that few older patients are referred for transplant approaches partially mitigates this 'inefficient' patient flow. Nonetheless, in a recent representative study, about 20% of patients who achieved remission were not randomized to post-remission treatment for these and other reasons.
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(2) AML in older individuals is extremely heterogeneous in its nature and some therapies might be appropriate for only certain AML subtypes and positive effects might be missed when applied to the overall AML population. (3) Strategies might need to be different if one is evaluating a cytotoxic drug that could not be added to standard therapy without dose reduction of the standard regimen, or a biologic agent that could be easily combined with the baseline regimen without dose modification. In recent years, a number of anticancer agents (including gemtuzumab ozogamicin in older patients with AML in first relapse) have been approved by the FDA based on phase II data alone in patients with advanced disease. 6 However, in AML in relapse, future cytotoxics might now have to be compared to gemtuzumab ozogamicin, although the modest response rates seen with gemtuzumab render it a far from invincible 'opponent'. While it is conceivable that another new cytotoxic might come along which could produce similar response rates in relapsed patients, short of the development of a uniquely selective molecule such as imatinib mesylate for chronic myeloid leukemia, the less targeted noncytotoxic therapies mentioned above are unlikely to produce dramatic responses if used as the only treatment for relapse.
Possible study designs for randomized trials of new therapies in patients in first CR are shown in Table 1 . Conventional therapy might refer to a few courses of Ara-c at a dose of 100 mg/m 2 , which results in 5 to 10% long-term diseasefree survival in such patients. This is slightly better than observation without treatment, which produces very if any longterm disease-free survivors and shorter CR durations. Given these poor results, it would be reasonable to compare new treatments with the Ara-c alone. Alternatively, new treatments could be compared to observation after completion of Ara-c. This design is less 'efficient' in that it can be predicted that a number of patients will drop out during the post-remission chemotherapy because of inability to tolerate further therapy. Optimally, if an agent can be safely combined with conventional therapy, it might be most efficient to utilize the new therapy in both induction and consolidation thereby perhaps maximizing the chance to detect antileukemic activity.
There are also questions about the most informative end point in terms of confidently identifying new active therapies. Would a statistically significant, but modest, prolongation of CR duration with a new agent be convincing enough to warrant its approval and eventual widespread use? Should the end point be median or overall survival? Should the end point be enhancing the cure fraction, which is arguably the most important goal in younger patients? Particularly in very old patients, long-term cure may be a less relevant consideration, and certainly would extend the period of observation needed to reach the study end point. In addition, because non-leukemic deaths are much more common in older, compared to younger patients, it might theoretically be tempting to censor non-leukemic deaths or focus only on relapse, so as to emphasize the 'cleanest' end point of antileukemic effect. It is frequently difficult to distinguish 'nonleukemic' deaths from death due to leukemia or complications of therapy, however.
These are difficult issues that may require a fairly large number of patients to show statistically significant differences in phase III trials. Therefore, only the most promising agents should be evaluated in such large, expensive trials. Given the large number of new approaches on the horizon, an initial Table 1 Possible study designs for the evaluation of new agents in older patients with AML in first remission New agent in both induction and post remission Conventional vs new agent Conventional ± noncytotoxic agent Conventional followed by: observation vs noncytotoxic Conventional followed by: observation vs cytotoxic Observation alone vs noncytotoxic approach could be to create a mechanism to quickly plug promising new agents into a series of adequately sized phase II studies in patients in remission using one of the designs in Table 1 , to try to identify the 'winners' to be selected for phase III testing. Such an effort would benefit from coordination among the cooperative groups, which have large numbers of older patients available for such trials, but which have been inefficient in the past in rapidly getting studies initiated. This scenario is also complicated by the fact that almost all of the new drugs are being developed by pharmaceutical companies who are inherently competitive with each other and impatient for rapid results. However, because the groups have the patients required for these important studies, administrative nimbleness with 'templated' phase II approaches, could hopefully address some of these practical constraints.
So what should be done for the older patient being seen tomorrow for whom there is no available study? As noted, this has to be a highly individualized decision that depends on the patient's medical and social condition, as well as the patient's individual goals about what he or she would like to do in the upcoming months, given that survival is likely to be less than 1 year. The occasional older patient with favorable cytogenetics should be offered more intensive therapy with curative intent, if medically feasible. There is no role for maintenance therapy. It also is not generally appropriate to rush into reinduction therapy when patients have evidence of early relapse because many can go for several months with observation, transfusion, and/or treatment with hydroxyurea. Hopefully, given the large number of intriguing compounds under development, imaginLeukemia ative clinical trials will become available for many of these patients in the near future.
